Abbott Laboratories (ABT) |
|
|
|
Abbott Laboratories Income Statement Quarterly
ABT
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
INCOME STATEMENT (Quarterly GAAP In millions $) |
(Dec 31 2022) IV. Quarter |
(Sep 30 2022) III. Quarter |
(Jun 30 2022) II. Quarter |
(Mar 31 2022) I. Quarter |
(Dec 31 2021) IV. Quarter |
Revenue From Contract With Customer Excluding Assessed Tax |
|
10,410.00 |
11,257.00 |
11,895.00 |
|
Revenue From Contract With Customer Excluding Assessed Tax |
|
- |
- |
- |
|
Total Revenue |
10,091.00 |
10,410.00 |
11,257.00 |
11,895.00 |
11,468.00 |
Cost of Goods and Services Sold |
4,593.00 |
4,629.00 |
4,933.00 |
4,987.00 |
4,766.00 |
Gross
Profit |
5,498.00 |
5,781.00 |
6,324.00 |
6,908.00 |
6,702.00 |
Selling, Administration, Marketing |
2,973.00 |
2,731.00 |
2,757.00 |
2,787.00 |
3,048.00 |
Depriciation & Amortization |
496.00 |
498.00 |
507.00 |
512.00 |
514.00 |
Research and Development Expense |
725.00 |
782.00 |
684.00 |
697.00 |
762.00 |
Restructuring charges |
- |
- |
- |
- |
- |
Other exp. /-income |
- |
- |
- |
- |
- |
Special Items |
- |
- |
- |
- |
- |
Total operating costs including COS |
8,787.00 |
8,640.00 |
8,881.00 |
8,983.00 |
9,090.00 |
Operating income/-loss
|
1,304.00 |
1,770.00 |
2,376.00 |
2,912.00 |
2,378.00 |
Other Deductions / - Income |
Interest expense |
154.00 |
141.00 |
132.00 |
131.00 |
131.00 |
Interest income |
- |
- |
- |
- |
- |
Net interest expense/-income |
154.00 |
141.00 |
132.00 |
131.00 |
131.00 |
Investment Income, Interest |
- |
- |
- |
- |
- |
Foreign Currency Transaction Gain (Loss), before Tax |
-14.00 |
19.00 |
- |
-3.00 |
-6.00 |
Sale of Assets |
- |
- |
- |
- |
- |
Financing Loss/ -Income |
- |
- |
- |
- |
- |
Other loss/ -income |
-156.00 |
-148.00 |
-108.00 |
-92.00 |
-74.00 |
Total costs & expenses |
8,771.00 |
8,652.00 |
8,905.00 |
9,019.00 |
9,141.00 |
Income /-loss before income taxes |
1,320.00 |
1,758.00 |
2,352.00 |
2,876.00 |
2,327.00 |
Income taxes expenses/-benefit |
287.00 |
323.00 |
334.00 |
429.00 |
338.00 |
Income after income taxes |
1,033.00 |
1,435.00 |
2,018.00 |
2,447.00 |
1,989.00 |
Net income/-loss
of other equity |
- |
- |
- |
- |
- |
Income/-loss
from cont. Ops. |
1,033.00 |
1,435.00 |
2,018.00 |
2,447.00 |
1,989.00 |
Accounting change |
- |
- |
- |
- |
- |
Discontinued operations |
- |
- |
- |
- |
- |
Extraordinary items |
- |
- |
- |
- |
- |
Net Income/-loss |
1,033.00 |
1,435.00 |
2,018.00 |
2,447.00 |
1,989.00 |
Noncontrolling interests |
- |
- |
- |
- |
- |
Prefered dividends |
- |
- |
- |
- |
- |
Other |
- |
- |
- |
- |
- |
Income/-loss to shareholder |
1,033.00 |
1,435.00 |
2,018.00 |
2,447.00 |
1,989.00 |
EBIT |
1,474.00 |
1,899.00 |
2,484.00 |
3,007.00 |
2,458.00 |
EBITD |
1,785.00 |
2,216.00 |
2,799.00 |
3,318.00 |
2,827.00 |
EBITDA |
2,281.00 |
2,714.00 |
3,306.00 |
3,830.00 |
3,341.00 |
Per
Share (GAAP Quarterly, in $) |
(Dec 31 2022) IV. Quarter |
(Sep 30 2022) III. Quarter |
(Jun 30 2022) II. Quarter |
(Mar 31 2022) I. Quarter |
(Dec 31 2021) IV. Quarter |
Basic EPS (excl. extra
items) |
0.59 |
0.82 |
1.15 |
1.38 |
1.12 |
Extraordinary items |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Basic Net EPS |
0.59 |
0.82 |
1.15 |
1.38 |
1.12 |
Basic shares outstanding (Mill.
of Units) |
1,743.26 |
1,752.97 |
1,753.87 |
1,761.91 |
1,769.44 |
EPS other shares |
- |
- |
- |
- |
- |
Diluted Net EPS |
0.59 |
0.81 |
1.14 |
1.37 |
1.12 |
Diluted average shares (Mill.
of Units) |
1,773.15 |
1,763.65 |
1,765.46 |
1,774.54 |
1,782.22 |
Dividend per share |
0.464 |
0.468 |
0.469 |
0.469 |
0.448 |
|
|